Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
Mahmoud Alhariri, Senior Attending Physician at Helios Universitätsklinikum Wuppertal, Hypertensiologe at Deutsche Hochdruckliga e.V. DHL, Lipidology Specialist at Deutsche Gesellschaft für Lipidologie e. V. (DGFL), shared a post on LinkedIn about a recent article by Wolfgang C. Winkelmayer et al., published in American Journal of Kidney Diseases, adding:
“Among patients with hemodialysis-treated kidney failure, compared with no anticoagulation, initiation of apixaban soon after newly diagnosed AF was associated with lower risks of ischemic stroke, a composite thromboembolic end point, and all-cause mortality but higher rates of clinically meaningful bleeding.”
Title: Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis
Authors: Wolfgang C. Winkelmayer, Kevin F. Erickson, Pascale Khairallah, Mingyue He, Maria E. Montez-Rath, Tara I. Chang, Jingbo Niu

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 19, 2026, 22:24Erik Nelson: Low Iron Can Raise A1c without Changing Blood Sugar
-
Nov 19, 2026, 22:23Erwin Loh: Daily Iron Supplementation Reduces Iron-Deficiency Anaemia in Children and Adolescents
-
Nov 19, 2026, 22:22Afifah Sardar: Why Can a Simple Painkiller like Aspirin Make You Bleed More?
-
Nov 19, 2026, 22:16Jonathan Penm: Perioperative Anticoagulation Management and Antithrombotic Stewardship Across 31 Countries
-
Nov 19, 2026, 22:15Salomao V.: Innovation in Hemophilia A Is Also About How Patients Receive Their Treatment
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing